98%
921
2 minutes
20
Cas9-linked deaminases, also called base editors, enable targeted mutation of single nucleotides in eukaryotic genomes. However, their off-target activity is largely unknown. Here we modify digested-genome sequencing (Digenome-seq) to assess the specificity of a programmable deaminase composed of a Cas9 nickase (nCas9) and the deaminase APOBEC1 in the human genome. Genomic DNA is treated with the base editor and a mixture of DNA-modifying enzymes in vitro to produce DNA double-strand breaks (DSBs) at uracil-containing sites. Off-target sites are then computationally identified from whole genome sequencing data. Testing seven different single guide RNAs (sgRNAs), we find that the rAPOBEC1-nCas9 base editor is highly specific, inducing cytosine-to-uracil conversions at only 18 ± 9 sites in the human genome for each sgRNA. Digenome-seq is sensitive enough to capture off-target sites with a substitution frequency of 0.1%. Notably, off-target sites of the base editors are often different from those of Cas9 alone, calling for independent assessment of their genome-wide specificities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/nbt.3852 | DOI Listing |
J Control Release
September 2025
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhizaoju Road, Shanghai 200011, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Lane. 833 Zhizaoju Road, Shanghai 200011, China; Department of Biomedical Engineerin
Radiotherapy (RT) is a mainstay of cancer treatment but is limited by tumor resistance and off-target tissue damage, often mediated by therapy-induced cellular senescence. Here, we developed a "one-two punch" nanodrug, Lipo@ABT263@Au, that integrated a senolytic agent (ABT-263) with a gold-shelled liposome for radiosensitization and sustained drug release. High-throughput screening and transcriptomic analysis identified senescence as a key RT-induced vulnerability.
View Article and Find Full Text PDFA longstanding barrier in genome engineering with CRISPR-Cas9 has been the inability to measure Cas9 edit outcomes and their functional effects at single-cell resolution. Here we present Superb-seq, a new technology that leverages T7 transcription and single-cell RNA sequencing to jointly measure on- and off-target Cas9 edits and their effects on gene expression. We performed Superb-seq on 10,000 K562 cells, targeting four chromatin remodeler genes with seven guide RNAs.
View Article and Find Full Text PDFbioRxiv
August 2025
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
DNA base editing is increasingly used for human genetic modification, but methods for monitoring off-target editing are nascent. Here we present a simple model-independent workflow for identifying sites of off-target base-editing in relevant cell types on a genome-wide level. We report that sites of off-target editing by the ABE8e editor could be identified using an ABE8e derivative with restored DSB cleavage activity.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
September 2025
Beijing National Laboratory for Molecular Sciences (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
CRISPR/Cas systems have transformed genome editing, yet achieving precise temporal and conditional control remains challenging. Traditional strategies involving linear guide RNAs (gRNAs) modified with multiple chemical groups throughout their strands often face limitations such as heterogeneous reaction outcomes, irreversibility, and variable editing efficiencies. To overcome these issues, topology-engineered guide RNAs (TE-gRNAs) have emerged, featuring defined structural architectures including polymeric, circular, and dendrimer-like topologies that enable precise spatial control, reversibility, and programmable activation of CRISPR activity.
View Article and Find Full Text PDFSmall
September 2025
Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.
The traditional disease treatment strategies typically encounter low therapeutic efficacy and high side effects originating from toxic drugs or surgeries, necessitating nontoxic approaches. The emerging pancatalytic medicine, rooted in respecting body ecology, offers a nontoxic protocol via catalyst preparation (P), biological effect activation (A), and versatile disease nontoxic-treatment (N). By precisely delivering catalysts to disease sites, it enables in situ catalytic chemical reactions that specifically target pathological microenvironments, e.
View Article and Find Full Text PDF